A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

July 29, 2019

Study Completion Date

July 29, 2019

Conditions
Asthma
Interventions
DRUG

AZD8154

SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).

Trial Locations (1)

14050

Research Site, Berlin

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY